NCT03234400View on ClinicalTrials.gov

A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

October 23, 2018

Study Completion Date

January 23, 2019

Conditions
HIV-1-infection
Interventions
COMBINATION_PRODUCT

Dapivirine Vaginal Ring, 25 mg

Vaginal Ring containing 25 mg dapivirine

COMBINATION_PRODUCT

Dapivirine Vaginal Ring, 100 mg

Vaginal Ring containing 100 mg dapivirine

COMBINATION_PRODUCT

Dapivirine Vaginal Ring, 200 mg

Vaginal Ring containing 200 mg dapivirine

Trial Locations (2)

35294

University of Alabama at Birmingham, Birmingham

94102

Bridge HIV CRS San Francisco Department of Public Health, San Francisco

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

International Partnership for Microbicides, Inc.

INDUSTRY

NCT03234400 - A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings | Biotech Hunter | Biotech Hunter